Stockscreener 앱 받기
7.635
3.60%
-0.275
전일 마감가:
$7.91
열려 있는:
$7.685
하루 거래량:
2.36M
Relative Volume:
0.40
시가총액:
$1.24B
수익:
$1.08B
순이익/손실:
$422.82M
주가수익비율:
3.3487
EPS:
2.28
순현금흐름:
$-637.33M
1주 성능:
-10.50%
1개월 성능:
-19.40%
6개월 성능:
+18.95%
1년 성능:
-16.39%
1일 변동 폭
$7.60
$7.86
1주일 범위
$7.60
$8.66
52주 변동 폭
$5.01
$11.55
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.635 | 1.28B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.08 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.04 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.57 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 재개 | H.C. Wainwright | Buy |
| 2025-08-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax Completes Nuvaxovid US Marketing Authorization Transfer to Sanofi - MarketScreener
Novavax transfers U.S. marketing rights for Nuvaxovid to Sanofi, triggering $25 million milestone payment - MarketScreener
Novavax completes US marketing transfer to Sanofi for COVID vaccine - Investing.com
Novavax (NASDAQ: NVAX) completes U.S. Nuvaxovid transfer to Sanofi, $25M milestone - Stock Titan
Signal strength of Novavax Inc. stock in tech scannersBear Alert & Technical Analysis for Trade Confirmation - newser.com
How Novavax Inc. (NVV1) stock gains from tech spendingWeekly Trend Recap & AI Driven Price Predictions - newser.com
Novavax Transfers Nuvaxovid Rights to Sanofi - TipRanks
NovavaxFDA approves transfer of Nuvaxovid authorization to SanofiSEC filing - MarketScreener
Novavax Inc Completes U.S. Marketing Authorization Transfer to Sanofi - TradingView
Can Novavax Inc. stock rebound after recent weaknessPortfolio Performance Summary & Technical Confirmation Trade Alerts - newser.com
Novavax (NASDAQ:NVAX) Share Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Market reaction to Novavax Inc.’s recent newsShare Buyback & AI Enhanced Market Trend Forecasts - newser.com
What moving averages say about Novavax Inc.Rate Cut & High Return Trade Opportunity Guides - newser.com
How Novavax Inc. (NVV1) stock moves on employment dataJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Why Novavax Inc. stock could rally in 2025Portfolio Return Report & Low Risk High Reward Trade Ideas - newser.com
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Benzinga
Relative strength of Novavax Inc. in sector analysis2025 Market Sentiment & Weekly High Return Opportunities - newser.com
Is Novavax Inc. stock in correction or buying zone2025 Trade Ideas & Weekly Momentum Picks - newser.com
How Novavax Inc. stock compares to market leadersMarket Activity Report & Real-Time Stock Price Movement Reports - newser.com
Key metrics from Novavax Inc.’s quarterly dataSell Signal & Smart Allocation Stock Tips - newser.com
How interest rate cuts could boost Novavax Inc. stockJuly 2025 Big Picture & Reliable Entry Point Trade Alerts - newser.com
Will breakout in Novavax Inc. lead to full recovery2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
Will Novavax Inc. (NVV1) stock benefit from sector leadershipWeekly Profit Analysis & High Conviction Buy Zone Alerts - newser.com
Novavax (NVAX) to Release Earnings on Thursday - MarketBeat
B. Riley Issues Pessimistic Outlook for Novavax Earnings - MarketBeat
Why Novavax Inc. stock remains on watchlistsGold Moves & High Yield Equity Trading Tips - newser.com
Can Novavax Inc. stock reach $100 price targetJuly 2025 Closing Moves & High Yield Stock Recommendations - newser.com
Can Novavax Inc. stock sustain market leadershipPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - MSN
Published on: 2025-10-31 05:03:55 - newser.com
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바백스 주식 (NVAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
1.32%
0.35%
자본화:
|
볼륨(24시간):